low - Cancer treatment demand is non-discretionary and largely insulated from economic cycles. However, hospital capital budgets for new therapy adoption and payer willingness to cover premium-priced treatments can be affected during severe recessions. The company's commercial trajectory depends more on clinical evidence generation and reimbursement policy than GDP growth.

Rising interest rates negatively impact valuation multiples for pre-profitable biotech companies as future cash flows are discounted more heavily. Higher rates increase the opportunity cost of holding cash-burning growth stocks versus fixed income. Operationally, Iovance benefits from interest income on its $1.2B+ cash balance, partially offsetting burn rate, but this is minor relative to the valuation compression effect. Financing costs for future capital raises increase in higher rate environments.

growth - Attracts speculative biotech investors focused on commercial execution of novel cell therapy platform with significant market expansion potential if pipeline succeeds. The stock appeals to those willing to accept high volatility and binary clinical/regulatory risk in exchange for multi-bagger potential if TIL therapy gains broader adoption across solid tumors. Not suitable for value or income investors given negative profitability, no dividend, and high cash burn.